In a preclinical study, it was established that the blockade of CD112R alone or together with TIGIT-blockade enhances the trastuzumab-triggered antitumor response in human NK cells and improves the efficacy of trastuzumab therapy for breast cancer.104,160,164 This finding suggests that CD112R on NK cells may be a potential target for breast cancer treatment in the future, although its efficacy and safety remain to be further verified through animal experiments and clinical trials. The gene discussed is PVRIG; the disease is breast carcinoma.